Medicinova Inc Common Stock (MNOV)
Stock · NASDAQ · Health Care
$1.43as of 10/16/2026
Price chart
Active signals
MNOV Signal Track Record
How signals performed across all stocks →What MNOV's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 50 | +0.2% | 50% | September 28, 2026 |
| Bollinger Band Breakdown | 21 | +2.4% | 62% | June 12, 2026 |
| Bollinger Band Breakout | 17 | -5.6% | 35% | September 3, 2026 |
| 200-Day Moving Average TouchActive now | 16 | -2.7% | 31% | October 9, 2026 |
| Any 20-session window (baseline) | -2.7% | 38% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About MNOV
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis,…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 6
- Website
- medicinova.com/
Fundamentals
- 1-day range
- $1.45$1.53
- Market cap
- $66.94M
- P/E (trailing)
- —
- P/E (forward)
- -2.82
- EPS (trailing)
- $-0.22
- Dividend yield
- —
- Beta
- 0.69
- Avg. volume
- 325.6K
How Medicinova Inc Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 10, 2026 · via SEC EDGAR / Finnhub
Forecasts
4 analyst ratings
Medicinova Inc Common Stock Competitors
Chosen by industry and closest market cap.
- MNOVMedicinova Inc Common Stock$1.42▼ 2.07%Market cap $66.94MP/E —$1.17$3.9
- RNTXRein Therapeutics Inc. Common Stock$0.59▼ 6.05%Market cap $67.45MP/E —$0.5401$2.18
- CINGCingulate Inc. Common Stock$4.36▼ 0.68%Market cap $68.02MP/E —$3.16$11.89
- CLNNClene Inc. Common Stock$3.1▼ 6.34%Market cap $68.24MP/E —$3.24$13.5
- PLRXPliant Therapeutics Inc. Common Stock$0.9▼ 7.41%Market cap $65.02MP/E —$0.8838$1.95
- IBIOiBio Inc. Common Stock$0.77▼ 1.28%Market cap $69.05MP/E —$0.7328$3.82
- ANVSAnnovis Bio Inc. Common Stock$0.99▼ 5.71%Market cap $64.44MP/E —$1.01$5.5
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| MNOV Medicinova Inc Common Stock | $66.94M | — | $1.42 | ▼ 2.07% | $1.17$3.9 |
| RNTX Rein Therapeutics Inc. Common Stock | $67.45M | — | $0.59 | ▼ 6.05% | $0.5401$2.18 |
| CING Cingulate Inc. Common Stock | $68.02M | — | $4.36 | ▼ 0.68% | $3.16$11.89 |
| CLNN Clene Inc. Common Stock | $68.24M | — | $3.1 | ▼ 6.34% | $3.24$13.5 |
| PLRX Pliant Therapeutics Inc. Common Stock | $65.02M | — | $0.9 | ▼ 7.41% | $0.8838$1.95 |
| IBIO iBio Inc. Common Stock | $69.05M | — | $0.77 | ▼ 1.28% | $0.7328$3.82 |
| ANVS Annovis Bio Inc. Common Stock | $64.44M | — | $0.99 | ▼ 5.71% | $1.01$5.5 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- MediciNova Provides Update On Recent Topline Results Of Its Phase 2 Clinical Trial Evaluating MN-001 For Treatment Of Nonalcoholic Fatty Liver Disease And Hypertriglyceridemia Associated With Type 2 Diabetes Mellitus; At End Of The 24-Week Period, Serum Triglycerides, Liver Fat, And Body Weight Were Also Reduced In The MN-001 Group Compared With Placebo, Although These Differences Did Not Reach Statistical Significancebenzinga · 10/12/2026
- MediciNova to Participate in the Maxim Growth SummitYahoo · 10/6/2026
- Let's take a look at the stocks that are in motion in today's session.ChartMill · 9/28/2026
- MediciNova Drug Falls Short on Liver Fat Parameter, Stock TumblesYahoo · 9/28/2026
- Let's uncover which stocks are experiencing notable gaps during today's session.ChartMill · 9/28/2026
- MediciNova Shares Fall After Phase 2 Tipelukast Trial Misses Primary EndpointsYahoo · 9/28/2026
- MediciNova stock tumbles on mixed Phase 2 NAFLD trial dataYahoo · 9/28/2026
- 12 Health Care Stocks Moving In Monday's Intraday SessionBenzinga · 9/28/2026
- MediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)Yahoo · 9/28/2026
Insider Activity
Insider Actions →- 3D Investment Partners Pte. Ltd. · September 25, 2026 · Sale640.0K @ $2.7
- Hideki Nagao · June 23, 2026 · Grant44.5K
- Lemerond Nicole · June 23, 2026 · Grant44.5K
- BEAVER CAROLYN · June 23, 2026 · Grant44.5K
Institutional Ownership
March 31, 2026
- Total shares held
- 5.09M
- Total value held
- $6.96M
- Institutional holders
- 27
- Unknown1.11M
- Unknown706.0K
- Unknown635.7K
- Unknown611.0K
- Unknown543.8K
- Unknown222.2K
- Unknown193.7K
- Unknown189.9K
- Unknown162.9K
- Unknown133.2K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
MediciNova Stock Drops After Phase 2 Trial Misses Goals
MediciNova shares fell sharply after topline results from its Phase 2 trial of tipelukast for NAFLD missed primary endpoints. The drug failed to meet the target for reducing liver fat, leading to a significant decline in the stock price. This negative data point contrasts with the company's previous analyst price targets, which are notably higher than the current trading levels.
MediciNova Stock Drops After Phase 2 Trial Misses Goals. MediciNova shares fell sharply after topline results from its Phase 2 trial of tipelukast for NAFLD missed primary endpoints. The drug failed to meet the target for reducing liver fat, leading to a significant decline in the stock price. This negative data point contrasts with the company's previous analyst price targets, which are notably higher than the current trading levels.